Full Press Release Details
Pharmaceuticals to Present at the 36th
Annual Cowan Health Care Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--February 29, 2016--Aurinia
Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that its
Chief Executive Officer, Stephen W. Zaruby will present a corporate
overview of the company at the 36th annual Cowan Health Care
Conference, taking place March 7-9, 2016 in Boston at the Boston
Marriott Hotel. The presentation will also be available using the
Aurinia Presentation Details
| Date: | Monday, March 7, 2016 | |
| Time: | 1:20 p.m. Eastern standard Time | |
| Location: | Berkeley Room, 3 rd flr | |
| Webcast: | http://wsw.com/webcast/cowen30/auph |
Aurinia is a clinical stage pharmaceutical company focused on the global
nephrology market. It is currently collecting data in its 265 patient
Phase 2b clinical trial to evaluate the efficacy of its drug,
voclosporin, as a treatment for lupus nephritis (LN). LN is an
inflammation of the kidneys, that if inadequately treated can lead to
end-stage renal disease, making LN a serious and potentially
life-threatening condition.
Voclosporin is a novel and potentially best-in-class calcineurin
inhibitor ("CNI") with extensive clinical data in over 2,000 patients in
other indications. Voclosporin is made by a modification of a single
amino acid of the cyclosporine molecule (a CNI approved for use in
transplant patients since 1983). This modification results in a more
predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency vs. cyclosporine, an altered metabolic profile, and
potential for flat dosing.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals Inc.
Martin, 250-708-4272
Chief Operating Officer
Financial Communications Inc.